# Design, synthesis, and biological evaluation of phenylisoxazole-based histone deacetylase inhibitors

## TL;DR

This study designs and tests new HDAC1 inhibitors that show strong anti-cancer activity in prostate cancer cells.

## Contribution

A new series of phenylisoxazole-based HDAC1 inhibitors with potent anti-proliferative activity is developed.

## Key findings

- Compound 17 showed 86.78% HDAC1 inhibition at 1000 nM.
- Compound 17 had an IC50 of 5.82 μM against prostate cancer PC3 cells.
- Compound 17 showed no significant toxicity to normal prostate cells.

## Abstract

Histone deacetylases (HDACs) mediate the removal of acetyl groups from lysine residues in both histone and non-histone proteins, and have been regarded as promising targets for drug discovery. As a central member of HDAC family, HDAC1 has been found to be closely linked to the occurrence and development of prostate cancer. In this study, we designed and synthesized a new series of 3-phenylisoxazole HDAC1 inhibitors based on the hit 7, identified by in-house compound library screening. The structure-activity relationship studies (SARs) indicated that the R1 position was relatively tolerated for activity. The linker length at R2 exerted a significant influence on activity with the relative orders of butyl > propyl > ethyl > methyl. Among synthetic 16 compounds, compound 17 indicated the strongest HDAC1 inhibitory effect with the inhibition rate of 86.78% at the concentration of 1000 nM. In addition, derivative 17 could not only well occupy the active pocket of HDAC1, but also showed favorable drug-like properties. More importantly, molecule 17 exerted potent anti-proliferative activity on prostate cancer PC3 cells with the IC50 value of 5.82 μM, and had no significant toxicity against normal prostate WPMY-1 cells. Collectively, these findings validate phenylisoxazole derivative 17 as a promising lead compound for further optimization and development.